US will still pay at least twice as much after negotiating drug prices
U.S. pays higher drug prices, gets priority access
Medicare's negotiated prices most significant for drugs with little competition
Goal is to balance affordability and innovation
Updates first graphic to align colors representing countries with second graphic
By Deena Beasley
Sept 3 (Reuters) -The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.
The U.S. Medicare health plan, which covers more than 67 million people, recently unveiled new maximum prices for the first 10 high-cost medicines negotiated under the Biden Administration's Inflation Reduction Act.
This is the first time Medicare has disclosed actual drug prices, which are largely hidden behind a complicated U.S. system of rebates and discounts. The lower prices will result in savings of $6 billion in 2026, the first year they take effect, Medicare said.
A Reuters review of publicly available maximum prices set by other wealthy nations - Australia, Japan, Canada and Sweden - show that they have negotiated far lower prices for the same drugs.
A 30-day supply of nine of the 10 drugs will cost $17,581 for Medicare in 2026, compared with $6,725 in Sweden this year. Comparable prices were not available for the 10th drug, Novo Nordisk's NOVOb.CO insulin Novolog.
"In the U.S. we've always accepted that we are the country that overpays relative to the rest of the world," said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University.
The U.S. sees value in being the preferred customer, she said, pointing to early availability of COVID vaccines as an example of that advantage.
Many countries have universal prescription drug coverage that relies on centralized price negotiation with manufacturers, but U.S. law previously prevented Medicare - the nation's single biggest government program - from doing so.
Bristol Myers BMY.N said pricing was country specific and depended on national health systems and their regulatory policies, while Merck MRK.N said it was not valid to compare U.S. prices to overseas generics. Amgen AMGN.O declined to comment and the others drugmakers did not respond.
A spokesperson for the U.S. agency that oversees Medicare said the new law requires consideration of factors such as manufacturer data and availability of alternative treatments, but Congress did not include review of international prices in the negotiations.
U.S. ALWAYS PAYS MORE
A study by the non-profit RAND Corp looking at 2022 prescription prices found that U.S. health plans paid more than three times as much for brand-name pharmaceuticals, even after estimated discounts.
Studies have shown that faster uptake of new and more expensive drugs helps drive U.S. prices, while other high-income countries directly footing the bill for healthcare place tighter restrictions on prescriptions.
The willingness of the U.S. to pay up for drugs also contributes to lower overseas prices, said Richard Frank, director of the Brookings Institution's Center on Health Policy.
"If you've got one of your buyers who's willing to cover your sunk costs, plus some of your ongoing costs," selling more volume to others, even at lower prices, can still be profitable, he said.
In some cases, lower-cost generic or biosimilar versions of the original branded drugs are already available outside the U.S. Generic versions of Merck's Januvia, for instance, have been on the market in Canada since late 2022, while U.S. patents for the diabetes drug are in place until 2026.
Once patents expire on a brand-name drug and copycat versions hit the market, prices fall sharply. But drugmakers are often able to extend U.S. patent coverage by making small changes to things like dosage or formulation.
There are still no U.S. biosimilar competitors for one of the most expensive of the negotiated drugs, Amgen's Enbrel, which was first approved in 1998 for rheumatoid arthritis. U.S. courts have upheld Amgen's patents, blocking biosimilars until 2029.
Other countries already have multiple options. Sweden's price for a 30-day supply of an Enbrel biosimilar is $709, compared with Medicare's newly-negotiated price of $2,355.
Since most drugmakers hike U.S. prices annually, "the longer a drug is in the U.S. market, the more we pay," said Mariana Socal, associate scientist at Johns Hopkins Bloomberg School of Public Health, noting that in other countries prices typically come down over time.
An analysis by the Brookings Institution showed that Medicare's negotiations yielded the biggest benefit for drugs with little market competition. It found that three drugs - Enbrel, Bristol Myers' and Pfizer's PFE.N blood thinner Eliquis, and Johnson & Johnson's JNJ.N Crohn's disease drug Stelara - will account for more than half of Medicare's expected $6 billion savings.
Even for the medicines with no generic competition outside the U.S., other governments have set lower prices.
The most Medicare agreed to pay for AstraZeneca's AZN.L diabetes drug Farxiga is $179 for a 30-day supply. Sweden's maximum price for 30 days of Farxiga's standard dose is $35, and the price in Canada is about $60.
Each year, more drugs will be up for price negotiation by Medicare, which accounts for about a third of U.S. drug spending.
"We're going to see the U.S. pushing the market ... so that the U.S. pays something that sort of does a better job of balancing affordability, innovation, and incentives," Brookings' Frank said.
Prices for drugs included in U.S. Medicare's first negotiations 2 https://reut.rs/3MrxHZ6
Prices for drugs included in U.S. Medicare's first negotiations Prices for drugs included in U.S. Medicare's first negotiations https://reut.rs/4e704r1
Reporting By Deena Beasley in Los Angeles; Additional reporting by Patrick Wingrove in New York; Editing by Caroline Humer and Bill Berkrot
Σχετιζόμενα σύμβολα
Τελευταία νέα
Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.
Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.
Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.
